The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation.
Open accessAbstract
BACKGROUND: Glucagon-like peptide-1 (GLP-1)(7-36) amide is an intestinal incretin hormone which also inhibits gastric acid secretion in humans. Its mechanism of action is unclear, but it strongly inhibits vagally induced secretion (sham feeding), suggesting that it could influence vagal activity. AIM/METHODS: The effect of intravenous GLP-1 (7-36 amide) (1 pmol/kg/min) was studied on pentagastrin induced acid secretion in otherwise healthy subjects, previously vagotomised for duodenal ulcer (n = 8) and in a group of young (n = 8) and old (n = 6) healthy volunteers. RESULTS: Pentagastrin increased acid secretion significantly in all three groups, but the plateau concentration in the vagotomised subjects was lower than in controls. Infusion of GLP-1 (7-36 amide) significantly inhibited acid secretion in the control groups (to 67 (SEM 6) and 74 (SEM 3)% of plateau concentrations in young and old controls, respectively) but had no effect in the vagotomised subjects. Differences in plasma concentrations of GLP-1 (7-36 amide), recovery of gastric marker, duodenal regurgitation, or Helicobacter pylori status could not explain the lack of effect. Blood glucose was lowered equally by GLP-1 (7-36 amide) in all subjects. CONCLUSION: The inhibitory effect of GLP-1 (7-36 amide) on acid secretion depends on intact vagal innervation of the stomach.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There is evidence that GLP-1, administered peripherally or centrally, inhibits vagal activity in animals and humans.
“In addition to regulating glycemia, there is evidence that the neuropeptide GLP-1, administered peripherally or centrally, inhibits vagal activity in animals and humans (19, 50, 51) and increases sympathetic activity in rats (52, 53).”
From Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans (2008) · cites this paper as [51]
The Discussion reports that peripherally infused GLP-1 inhibited vagally induced gastric acid secretion in humans and cites a similar finding in pigs. It infers an interaction with vagal pathways, but does not demonstrate inhibition of vagal activity itself; central action is proposed as a possibility, not tested by central administration. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · see citing works
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · see citing works
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · see citing works
Self-citationTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 916 · see citing works
Self-citationMojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724 · see citing works
Elliott, R. M., Morgan, L. M., Tredger, J. A., Deacon, S., Wright, J., & Marks, V. (1993) · Journal of Endocrinology · doi:10.1677/joe.0.1380159 · Cited by 695 · see citing works
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · see citing works
Self-citationTruncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Nielsen, O. V., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 611 · see citing works
Self-citationExon duplication and divergence in the human preproglucagon gene
Bell, G. I., Sanchez-Pescador, R., Laybourn, P. J., & Najarian, R. C. (1983) · Nature · doi:10.1038/304368a0 · Cited by 593 · see citing works
Ørskov, C., Holst, J. J., Knuhtsen, S., Baldissera, F. G. A., Poulsen, S. S., & Nielsen, O. V. (1986) · Endocrinology · doi:10.1210/endo-119-4-1467 · Cited by 484 · see citing works
Self-citationGöke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474 · see citing works
Ørskov, C., Poulsen, S. S., Mørten, M., & Holst, J. J. (1996) · Diabetes · doi:10.2337/diab.45.6.832 · Cited by 303 · see citing works
Self-citationGlucagon-like peptide-1, a new hormone of the entero-insular axis
Ørskov, C. (1992) · Diabetologia · doi:10.1007/bf00429088 · Cited by 294 · see citing works
Ørskov, C., Wettergren, A., & Holst, J. J. (1996) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529609009147 · Cited by 271 · see citing works
Self-citationGlucagonostatic and Insulinotropic Action of Glucagonlike Peptide I-(7–36)-Amide
Komatsu, R., Matsuyama, T., Namba, M., Watanabe, N., Itoh, H., Kôno, N., & Tarui, S. (1989) · Diabetes · doi:10.2337/diab.38.7.902 · Cited by 235 · see citing works
Ileal release of glucagon-like peptide-1 (GLP-1)
Layer, P., Holst, J. J., Grandt, D., & Goebell, H. (1995) · Digestive Diseases and Sciences · doi:10.1007/bf02064202 · Cited by 216 · see citing works
Self-citationPancreatic and intestinal processing of proglucagon in man
Ørskov, C., Holst, J. J., Poulsen, S. S., & Kirkegaard, P. O. (1987) · Diabetologia · doi:10.1007/bf00274797 · Cited by 210 · see citing works
Self-citationHvidberg, A., Nielsen, M.-B., Hilsted, J., Ørskov, C., & Holst, J. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90164-3 · Cited by 195 · see citing works
Self-citationSchjoldager, B., Mortensen, P. E., Christiansen, J., �rskov, C., & Holst, J. J. (1989) · Digestive Diseases and Sciences · doi:10.1007/bf01540341 · Cited by 178 · see citing works
Self-citationIdentification and Localization of Glucagon-Like Peptide-1 and Its Receptor in Rat Brain*
Shimizu, I., Hirota, M., Ohboshi, C., & Shima, K. (1987) · Endocrinology · doi:10.1210/endo-121-3-1076 · Cited by 174 · see citing works
Vagal mediation of the cholecystokinin satiety effect in rats
LORENZ, D., & Goldman, S. A. (1982) · Physiology & Behavior · doi:10.1016/0031-9384(82)90226-8 · Cited by 139 · see citing works
Wettergren, A., Petersen, H., ørskov, C., Christiansen, J., Sheikh, S. P., & Holst, J. J. (1994) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529409092462 · Cited by 133 · see citing works
Self-citationVarndell, I. M., Bishop, A. E., Sikri, K. L., UTTENTHAL, L. O., Bloom, S. R., & Polak, J. M. (1985) · Journal of Histochemistry & Cytochemistry · doi:10.1177/33.10.3900195 · Cited by 130 · see citing works
Glucagon-like peptide-1 (7–36)-NH2: a physiological inhibitor of gastric acid secretion in man
O’Halloran, D., Nikou, G. C., Kreymann, B., Ghatei, M. A., & Bloom, S. R. (1990) · Journal of Endocrinology · doi:10.1677/joe.0.1260169 · Cited by 91 · see citing works
Autoradiographic localization of receptors for glucagon-like peptide-1(7–36) amide in rat brain
UTTENTHAL, L. O., Tolédano, A., & Blázquez, E. (1992) · Neuropeptides · doi:10.1016/0143-4179(92)90036-v · Cited by 87 · see citing works
Olbe, L. C., Hamlet, A., Dalenbäck, J., & Fändriks, L. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8613042 · Cited by 73 · see citing works
Determination of Serum or Plasma Glucose on the "AutoAnalyzer II" by Use of the Hexokinase Reaction
Widdowson, G. M., & Penton, J. R. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.3.299 · Cited by 40 · see citing works
Holst, J. J., Rasmussen, T. N., Harling, H., & Schmidt, P. (1993) · Pancreas · doi:10.1097/00006676-199301000-00015 · Cited by 37 · see citing works
Self-citationAndersen, L. P., Espersen, F., Součková, A., et al. (1995) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.2.2.156-159.1995 · Cited by 37 · see citing works
Interaction between Secretin and Cholecystokinin on Inhibition of Gastric Secretion in Man
Henriksen, F. W., Sp, J., & Möller, S. (1974) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.1974.12096904 · Cited by 30 · see citing works
Holst, J. J., Skak‐Nielsen, T., Ørskov, C., et al. (1992) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529209000139 · Cited by 18 · see citing works
Self-citationGlucagonostatic and Insulinotropic Action of Glucagonlike Peptide 1－（7－36）－Amide
小松, 良. (1990) · Cited by 13 · see citing works
Flagged first, then by citations
Research works printed but not linked: 5
- 0rskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Production and secretion of amidated and glycine- extended glucagon-like peptide-1 (GLP-1) in man. Diabetes 1994; 43: 535-9.
- Goke R, Richter G, Kolligs F, Fehmann HC, Arnold R, Goke B. How do individual meal constituents influence the release of GLP-1 in humans [abstract]? Digestion 1993; 54:380.
- Wettergren A, Maina P, Boesby S, Hoist JJ. The effect of GLP-1 and PYY on acid secretion in man [abstract]. Regul Pept 1996; 64: 208.
- Holst JJ, Wettergren A, Wojdemann M, Poulsen SS, 0rskov C. Glucagon-like peptide-I (GLP-1): an important enterogastrone acting via the central nervous system. Hepatogastroenterology 1995; 42: 107 1.
- Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-1: brain, heart and pancreatic forms have the same deduced amino acid sequeftces. FEBSLett 1995; 358: 319-24.
Cited by
Sorted by citations
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works
Self-citationThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · see citing works
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · see citing works
Self-citationThe role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · see citing works
Transcellular Stomach Absorption of a Derivatized Glucagon-Like Peptide-1 Receptor Agonist
Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar7047 · Cited by 553 · see citing works
Ileal brake: a sensible food target for appetite control. A review
Maljaars, P. W. J., Peters, H. P. F., Mela, D. J., & Masclee, A. A. M. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.07.018 · Cited by 451 · see citing works
Glucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288 · see citing works
Delgado-Aros, S., Kim, D.-Y., Burton, D. D., Thomforde, G. M., Stephens, D., Brinkmann, B. H., Vella, A., & Camilleri, M. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2002.282.3.g424 · Cited by 235 · see citing works
The physiology of gastric emptying
Hellström, P. M., Grybäck, P., & Jacobsson, H. (2006) · Best Practice & Research Clinical Anaesthesiology · doi:10.1016/j.bpa.2006.02.002 · Cited by 223 · see citing works
Meier, J. J., Kemmeries, G., Holst, J. J., & Nauck, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2212 · Cited by 146 · see citing works
Self-citationThe role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications
Madsbad, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12119 · Cited by 146 · see citing works
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Koliaki, C., & Doupis, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0002-3 · Cited by 140 · see citing works
Schirra, J., Wank, U., Arnold, R., Göke, B., & Katschinski, M. (2002) · Gut · doi:10.1136/gut.50.3.341 · Cited by 130 · see citing works
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125 · see citing works
Self-citationBharucha, A. E., Charkoudian, N., Andrews, C. N., Camilleri, M., Sletten, D., Zinsmeister, A. R., & Low, P. A. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00153.2008 · Cited by 98 · see citing works
Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective
Nauck, M. A. (1998) · Acta Diabetologica · doi:10.1007/s005920050116 · Cited by 94 · see citing works
Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4
Baraboi, E.-D., St-Pierre, D. H., Shooner, J., Timofeeva, E., & Richard, D. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00424.2010 · Cited by 79 · see citing works
GLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
Roth, J. D., Erickson, M. R., Chen, S., & Parkes, D. G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01537.x · Cited by 74 · see citing works
Quast, D. R., Schenker, N., Menge, B. A., Nauck, M. A., Kapitza, C., & Meier, J. J. (2020) · Diabetes Care · doi:10.2337/dc20-0720 · Cited by 64 · see citing works
Mechanisms behind GLP-1 induced weight loss
Larsen, P. J. (2008) · The British Journal of Diabetes & Vascular Disease · doi:10.1177/1474651408100525 · Cited by 28 · see citing works
GLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26 · see citing works
Andrews, C. N., Bharucha, A. E., Camilleri, M., Low, P. A., Seide, B. M., Burton, D. D., Nickander, K. K., Baxter, K. L., & Zinsmeister, A. R. (2007) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2007.00923.x · Cited by 26 · see citing works
- Authors
- Wettergren, A., Wøjdemann, M., Meisner, S., Stadil, F., & Holst, J. J.
- Affiliations
- Rigshospitalet (DK)
- Venue
- Gut
- Publisher
- BMJ
- Published
- 1997-05
- Volume
- 40
- Issue
- 5
- Pages
- 597-601
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- PMC
- PMC1027160
- OpenAlex
- W2071966058
- Cited by
- 153
- References
- 32
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 4 · 2023: 1 · 2022: 7 · 2021: 2 · 2020: 1 · 2019: 6 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 3 · 2014: 6 · 2013: 8 · 2012: 9
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gut (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- glucagon-like peptide-1, GLP-1(7-36)amide, gastric acid secretion, vagal innervation, vagotomy, pentagastrin stimulation, incretins, duodenal ulcer, Helicobacter pylori, age differences, blood glucose
- MeSH terms
- Adult, Aged, Blood Glucose, Duodenal Ulcer, Glucagon-Like Peptides, Female, Gastric Acid, Gastric Mucosa, Glucagon, Humans, Male, Middle Aged, Pentagastrin, Peptide Fragments, Vagotomy, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
